help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meldrum, D. R.
Right arrow Articles by Judd, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meldrum, D. R.
Right arrow Articles by Judd, H. L.

Journal of Clinical Endocrinology & Metabolism, Vol 54, 1081-1083, Copyright © 1982 by Endocrine Society

ARTICLES

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

DR Meldrum, RJ Chang, J Lu, W Vale, J Rivier and HL Judd

Five women with endometriosis were given a daily dose of a potent long- acting GnRH agonist, D-Trp6-Pro9-Net-LHRH (GnRH-A) for 28 days in an attempt to suppress ovarian estrogen secretion. The mean level of estradiol (E2) during sampling over 24 hours decreased (P less than 0.01) from 62 +/- 11 to 10 +/- 1 pg/ml at the end of treatment. Mean concentrations of androstenedione, testosterone, estrone and E2 on day 28 of therapy were similar to those measured in oophorectomized women. The level of FSH was decreased (P less than 0.001) during GnRH-a, whereas that of LH was significantly (P less than 0.001) increased, suggesting differing intracellular control mechanisms for release of the two gonadotropins. Desensitization of the pituitary was demonstrated at the end of treatment by a complete lack of acute response of FSH or LH to the daily dose of GnRH-a. "Medical oophorectomy" provides a new approach to the treatment of endometriosis.


This article has been cited by other articles:


Home page
 NEJMHome page
D. L. Olive
Gonadotropin-Releasing Hormone Agonists for Endometriosis
N. Engl. J. Med., September 11, 2008; 359(11): 1136 - 1142.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Hirata, Y. Osuga, O. Yoshino, Y. Hirota, M. Harada, Y. Takemura, C. Morimoto, K. Koga, T. Yano, O. Tsutsumi, et al.
Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein
Hum. Reprod., August 1, 2005; 20(8): 2092 - 2096.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. C. Feinberg, J. G. Bromer, and W. H. Catherino
The Evolution of in Vitro Fertilization: Integration of Pharmacology, Technology, and Clinical Care
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 935 - 942.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. A. Amama, M. Taga, and H. Minaguchi
The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society